Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
291. |
ECCT/13/04/08 | Switching At Low HIV-1 RNA Into Fixed Dose Combinations SALIF Protocol Number: TMC278IFD3002 Amendment INT-1 |
Principal Investigator(s) 1. Edwin Onyango WERE 2. Milton Tony OMONDI 3. Gina OUATTARA 4. Gaudensia Nzembi MUTUA 5. Reena SHAH Site(s) in Kenya 1. Aga Khan University Hospital (Nairobi City county) 2. KEMRI/Walter-Reed Project Kombewa (Kisumu county) 3. Partners in Prevention (Uasin Gishu county) 4. Kenya AIDS Vaccine Initiative - KNH (Nairobi City county) 5. Kenya AIDS Vaccine Initiative - Kangemi (Nairobi City county) |
30-07-2012 |
View |
292. |
ECCT/20/04/02 | PROSYNK Study A 4-arm, open-label, individually randomized, controlled, phase-2, study of a probiotic and two synbiotics in young children in western Kenya. |
Principal Investigator(s) 1. Stephen Allen Site(s) in Kenya 1. Homa Bay County Referral Hospital (Homa Bay county) 2. Siaya County Referral Hospital (Siaya county) 3. Migori County Referral Hospital (Migori county) 4. Rongo Sub-County Hospital (Migori county) 5. Rachuonyo Sub County Hospital (Homa Bay county) 6. Kendu Bay Sub-County Hospital (Homa Bay county) 7. Ahero County Hospital (Kisumu county) 8. Rabuor Sub-County Hospital (Kisumu county) 9. Akala Sub-County Hospital (Siaya county) 10. Bondo Sub-County Hospital (Siaya county) |
05-08-2020 |
View |
293. |
ECCT/17/03/01 | The POWER cohort A cohort for evaluation of open-label PrEP delivery among Kenyan and South African women |
Principal Investigator(s) 1. Dr. Stella Njuguna Site(s) in Kenya 1. Jaramogi Oginga Odinga Teaching and Referral Hospital. (Kisumu county) |
04-05-2017 |
View |
294. |
ECCT/22/08/02 | AIM-LVRNA009-II_III-01 A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 2/3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) for the Prevention of COVID-19 in Participants Aged 18 Years and Olde |
Principal Investigator(s) 1. Bernhards Ogutu 2. Lucas Otieno 3. Videlis Nduba 4. Bernhards Ogutu 5. Jacqueline Mirera 6. Jacqueline Mirera Site(s) in Kenya 1. Siaya Clinical Trials Unit (Siaya county) 2. Homa Bay Clinical Trials Unit (Homa Bay county) 3. Ahero Clinical Trials Unit (Kisumu county) 4. CREA-N Machakos (Machakos county) 5. CREA-N Nakuru (Nakuru county) 6. Victoria Biomedical Research Institue (Kisumu county) |
22-11-2022 |
View |
295. |
ECCT/21/03/01 | Recombinant COVID-19 vaccine A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells), for the prevention of COVID-19 in adults aged 18 years and older |
Principal Investigator(s) 1. Walter Jaoko Jaoko Site(s) in Kenya KAVI-institute of Clinical Research |
13-05-2021 |
View |
296. |
ECCT/25/05/05 | Hibiscus 2 - Site 252 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Videlis Nduba Site(s) in Kenya 1. KEMRI CRDR Siaya Clinical Research Annex (Siaya county) |
15-10-2025 |
View |
297. |
ECCT/25/05/03 | Hibiscus 2 - Site 253 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya 1. Site 253 - International Cancer Institute (Uasin Gishu county) |
25-11-2025 |
View |
298. |
ECCT/25/05/06 | Hibiscus 2 - Site 254 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Doreen Mutua Site(s) in Kenya 1. Site 254 - Gertrude\'s Children\'s Hospital (Nairobi City county) |
26-11-2025 |
View |
299. |
ECCT/25/05/02 | Hibiscus 2 - Site 251 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. Site 251 - Ahero Clinical Trails Unit, CREATES Strathmore University (Kisumu county) |
16-12-2025 |
View |
300. |
ECCT/25/04/04 | LIMIT A Low INR to Minimize bleeding with mechanical valves Trial (LIMIT) |
Principal Investigator(s) 1. Anthony KIBUKA Gikonyo Site(s) in Kenya The Karen Hospital |
12-11-2025 |
View |